Paracetamolo S.A.L.F. (Paracetamol)

Paracetamol works by inhibiting the enzyme cyclooxygenase in the central nervous system, which reduces the production of prostaglandins. This action lowers the perception of pain and resets the hypothalamic temperature set‑point, providing analgesic and antipyretic effects.

The appropriate dose of Paracetamolo S.A.L.F. is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and response. Healthcare professionals should follow local guidelines and the product’s prescribing information.

Safety data for intravenous paracetamol in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against any possible risks and consider alternative therapies when appropriate. Consultation with a specialist is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with oral paracetamol, the intravenous form provides faster onset of action and is useful when oral administration is not feasible. It differs from NSAIDs by lacking significant anti‑inflammatory activity and having a lower risk of gastrointestinal irritation, but it shares the need for liver function monitoring.

Paracetamolo S.A.L.F. should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Ensure the vial is kept upright and avoid exposure to extreme temperatures.

The product is administered intravenously by a qualified healthcare professional. It is typically diluted in an appropriate compatible solution and infused over a short period, following aseptic technique and institutional protocols.

Serious risks include severe allergic reactions such as anaphylaxis, hepatic injury especially in patients with pre‑existing liver disease, and rare blood disorders. Prompt recognition and medical intervention are essential if these events occur.

Patients with known hypersensitivity to paracetamol or any component of the formulation, those with severe hepatic impairment, and individuals who have experienced serious adverse reactions to paracetamol should avoid using this product.